2-azido-4-nitrobenzaldehyde | 262863-78-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-azido-4-nitrobenzaldehyde
• CAS: 262863-78-5
• 化学式: C₇H₄N₄O₃
• 分子量: 192.134
• InChiKey: KKHZFCUOBSLLKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-azido-4-nitrobenzaldehyde 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 三苯基膦 、 tin(ll) chloride 作用下， 以 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 2.0h， 生成 Methyl 2-(2-chloro-3-pyridinyl)-8-[(3.5-dichloroisonicotinoyl)amino]-3H-1.3-benzodiazepine-4-carboxylate
  参考文献：
  名称：

  Dehydrophenylalanine derivatives as VLA-4 integrin antagonists

  摘要：

  We describe a series of dehydrophenylalanine derivatives where the Z isomers are potent VLA-4 antagonists but are subject to rapid biliary clearance and the E isomers have poor activity but have a slower rate of clearance. These configurationally constrained molecules have led to the design of a novel class of benzodiazepine VLA-4 antagonists. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00019-2
• 作为产物：
  描述：

  2-氨基-4-硝基苯甲醇 在 盐酸 、 manganese(IV) oxide 、 sodium nitrite 作用下， 以 二氯甲烷 为溶剂， 生成 2-azido-4-nitrobenzaldehyde
  参考文献：
  名称：

  Dehydrophenylalanine derivatives as VLA-4 integrin antagonists

  摘要：

  We describe a series of dehydrophenylalanine derivatives where the Z isomers are potent VLA-4 antagonists but are subject to rapid biliary clearance and the E isomers have poor activity but have a slower rate of clearance. These configurationally constrained molecules have led to the design of a novel class of benzodiazepine VLA-4 antagonists. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00019-2

文献信息

• 10.1002/cjoc.202400306
  作者：Xie, Zu-Kui、Ding, Jun-Jun、Ou, Yi-Ming、Shi, Jun-Xiu、Shen, Meng-Lan、Yao, Chuan-Zhi、Jiang, Hua-Jie、Yu, Jie

  DOI：10.1002/cjoc.202400306

  日期：——

  Herein, we reported a precise de novo synthesis of chiral 3,4-dihydroquinazoline frameworks via a one-pot anionic stereogenic-at-cobalt(III) complex-catalyzed enantioselective Ugi-azide/Pd-catalyzed cyclization sequence. This powerful protocol involves 5 components and 2 catalytic systems, delivering chiral 3,4-dihydroquinazolines with excellent enantioselectivities (up to 94% ee). The preliminary

  在此，我们报道了通过一锅阴离子立体异构钴(III)络合物催化的对映选择性Ugi-叠氮/Pd催化环化序列精确从头合成手性3,4-二氢喹唑啉骨架。这一强大的方案涉及 5 个组分和 2 个催化系统，可提供具有出色对映选择性（高达 94% ee）的手性 3,4-二氢喹唑啉。初步的抗真菌实验表明，Ugi加合物和3,4-二氢喹唑啉在抑制绿色木霉和禾谷镰刀菌等植物病原体方面具有巨大的潜力。
• 1,3-BENZODIAZEPINES WITH INTEGRIN INHIBITORY ACTIVITY FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS
  申请人：CELLTECH THERAPEUTICS LIMITED

  公开号：EP1117658A1

  公开（公告）日：2001-07-25
• US6274577B1
  申请人：——

  公开号：US6274577B1

  公开（公告）日：2001-08-14
• [EN] 1,3-BENZODIAZEPINES WITH INTEGRIN INHIBITORY ACTIVITY FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] 1,3-BENZODIAZEPINES POSSEDANT UNE ACTIVITE INHIBANT L'INTEGRINE UTILES POUR TRAITER DES TROUBLES INFLAMMATOIRES
  申请人：CELLTECH THERAPEUTICS LTD

  公开号：WO2000018760A1

  公开（公告）日：2000-04-06

  1,3-Benzodiazapine derivatives of formula (1) are described wherein Ar1 is an aromatic or heteroaromatic group; L1 is a linker atom or group; Ar2 is an optionally substituted aromatic or heteroaromatic group; R5 is a carboxylic acid (-CO¿2?H) or a derivative thereof. The compounds are able to inhibit the binding of alpha 4 integrins to their ligands and are of use in the prophylaxis and treatment of immune in inflammatory disorders.
• Dehydrophenylalanine derivatives as VLA-4 integrin antagonists
  作者：John R. Porter、Sarah C. Archibald、Julien A. Brown、Kirstie Childs、David Critchley、John C. Head、Ted A.H. Parton、Martyn K. Robinson、Anthony Shock、Richard J. Taylor、Graham J. Warrellow

  DOI：10.1016/s0960-894x(03)00019-2

  日期：2003.3

  We describe a series of dehydrophenylalanine derivatives where the Z isomers are potent VLA-4 antagonists but are subject to rapid biliary clearance and the E isomers have poor activity but have a slower rate of clearance. These configurationally constrained molecules have led to the design of a novel class of benzodiazepine VLA-4 antagonists. (C) 2003 Elsevier Science Ltd. All rights reserved.